Article Cited by others

RESEARCH

Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer

Kuznetsova Ekaterina B, Kekeeva Tatiana V, Larin Sergei S, Zemlyakova Valeria V, Khomyakova Anastasiya V, BabenkBabenko Olga V, Nemtsova Marina V, Zaletayev Dmitry V, Strelnikov Vladimir V

Year : 2007| Volume: 6| Issue : 1 | Page no: 9-9

   This article has been cited by
 
1 Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
George C. Prendergast,Courtney Smith,Sunil Thomas,Laura Mandik-Nayak,Lisa Laury-Kleintop,Richard Metz,Alexander J. Muller
Cancer Immunology, Immunotherapy. 2014;
[Pubmed]  [Google Scholar] [DOI]
2 Bridging integrator 1 (BIN1): form, function, and Alzheimerćs disease
Meng-Shan Tan,Jin-Tai Yu,Lan Tan
Trends in Molecular Medicine. 2013; 19(10): 594
[Pubmed]  [Google Scholar] [DOI]
3 Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors
Elizabeth S. McKenna,Pablo Tamayo,Yoon-Jae Cho,Erik J. Tillman,E. Lorena Mora-Blanco,Courtney G. Sansam,Edward C. Koellhoffer,Scott L. Pomeroy,Charles W.M. Roberts
Cell Cycle. 2012; 11(10): 1956
[Pubmed]  [Google Scholar] [DOI]
4 MYC, PARP1, and chemoresistance: BIN there, done that?
Ganesan, S.
Science Signaling. 2011; 4(166): art 15
[Pubmed]  [Google Scholar]
5 DNA fingerprinting techniques for the analysis of genetic and epigenetic alterations in colorectal cancer
Samuelsson, J.K., Alonso, S., Yamamoto, F., Perucho, M.
Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 2010; 693(1-2): 61-76
[Pubmed]  [Google Scholar]
6 Novel tools for unbiased DNA differential methylation screening
Tanas, A.S., Shkarupo, V.V., Kuznetsova, E.B., Zaletayev, D.V., Strelnikov, V.V.
Epigenomics. 2010; 2(2): 325-333
[Pubmed]  [Google Scholar]
7 Novel tools for unbiased DNA differential methylation screening
Alexander S Tanas,Viktoria V Shkarupo,Ekaterina B Kuznetsova,Dmitry V Zaletayev,Vladimir V Strelnikov
Epigenomics. 2010; 2(2): 325
[Pubmed]  [Google Scholar] [DOI]
8 Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: From biochemistry to clinical development
Rutella, S., Bonanno, G., De Cristofano, R.
Endocrine, Metabolic and Immune Disorders - Drug Targets. 2009; 9(2): 151-177
[Pubmed]  [Google Scholar]

 

Read this article